

To: (10)(2e) (10)(2e) @rivm.nl; (10)(2e) (10)(2e) (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl;  
From: (10)(2e)  
Sent: Thur 10/1/2020 2:12:03 PM  
Subject: RE: concept offerte Covid-19 thema 16 - impact op zorgsysteem  
Received: Thur 10/1/2020 2:12:03 PM

Thank you, (10)(2e) for this update.

I don't know if similar initiatives have started on devices and protection equipment as well. The product of the proposal might than just be an overview of these initiatives in combination with lessons learned in our testing facility.

Kind regards, (10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl>  
Sent: donderdag 1 oktober 2020 11:34  
To: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>  
Subject: RE: concept offerte Covid-19 thema 16 - impact op zorgsysteem

Dear Colleagues

I hope you are all doing well.

@ (10)(2e) and (10)(2e) - I have no comments on the paragraph related to the idea we brought forward.

@ (10)(2e) - (10)(2a) about setting up a list of essential or critical medicines, also in relation to activities within the pharmaceutical committee, in light of lessons learnt from the COVID-19 crisis and experiences from shortages. VWS-GMT's position therein has been that any medicine can be considered critical when it is needed and they have asked for a debate on the scope and need for such a listing. CBG has also had discussions about key APIs, or APIs and products with greater likelihood of shortages/vulnerability. These are aspects that could be relevant to your proposal.

Met vriendelijke groet,  
Kind Regards,

(10)(2e)  
(10)(2e) (10)(2e) (10)(2e) (10)(2e)  
(10)(2e)  
National Institute for Public Health and the Environment (RIVM)  
Centre for Health Protection (GZB)  
(10)(2e)  
P.O.Box 1, 3720 BA, Bilthoven, the Netherlands  
Tel: (10)(2e)  
Email: (10)(2e)@rivm.nl  
(10)(2e)

(10)(2e) (10)(2e)  
(10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e)  
(10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e)  
(10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e)  
(10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e) (10)(2e)  
(10)(2e) (10)(2e)